218 related articles for article (PubMed ID: 37924830)
21. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.
Martinez FJ; Calverley PM; Goehring UM; Brose M; Fabbri LM; Rabe KF
Lancet; 2015 Mar; 385(9971):857-66. PubMed ID: 25684586
[TBL] [Abstract][Full Text] [Related]
22. Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials.
Bernstein JA; Virchow JC; Murphy K; Maspero JF; Jacobs J; Adir Y; Humbert M; Castro M; Marsteller DA; McElhattan J; Hickey L; Garin M; Vanlandingham R; Brusselle G
Lancet Respir Med; 2020 May; 8(5):461-474. PubMed ID: 32066536
[TBL] [Abstract][Full Text] [Related]
23. A multi-center randomized, controlled, open-label trial evaluating the effects of eosinophil-guided corticosteroid-sparing therapy in hospitalised patients with COPD exacerbations - The CORTICO steroid reduction in COPD (CORTICO-COP) study protocol.
Sivapalan P; Moberg M; Eklöf J; Janner J; Vestbo J; Laub RR; Browatzki A; Armbruster K; Wilcke JT; Seersholm N; Weinreich UM; Titlestad IL; Andreassen HF; Ulrik CS; Bødtger U; Nielsen TL; Hansen EF; Jensen JUS
BMC Pulm Med; 2017 Aug; 17(1):114. PubMed ID: 28810909
[TBL] [Abstract][Full Text] [Related]
24. Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial.
Rabe KF; Celli BR; Wechsler ME; Abdulai RM; Luo X; Boomsma MM; Staudinger H; Horowitz JE; Baras A; Ferreira MA; Ruddy MK; Nivens MC; Amin N; Weinreich DM; Yancopoulos GD; Goulaouic H
Lancet Respir Med; 2021 Nov; 9(11):1288-1298. PubMed ID: 34302758
[TBL] [Abstract][Full Text] [Related]
25. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial.
Zheng JP; Wen FQ; Bai CX; Wan HY; Kang J; Chen P; Yao WZ; Ma LJ; Li X; Raiteri L; Sardina M; Gao Y; Wang BS; Zhong NS;
Lancet Respir Med; 2014 Mar; 2(3):187-94. PubMed ID: 24621680
[TBL] [Abstract][Full Text] [Related]
26. Amoxicillin-clavulanate versus azithromycin for respiratory exacerbations in children with bronchiectasis (BEST-2): a multicentre, double-blind, non-inferiority, randomised controlled trial.
Goyal V; Grimwood K; Byrnes CA; Morris PS; Masters IB; Ware RS; McCallum GB; Binks MJ; Marchant JM; van Asperen P; O'Grady KF; Champion A; Buntain HM; Petsky H; Torzillo PJ; Chang AB
Lancet; 2018 Oct; 392(10154):1197-1206. PubMed ID: 30241722
[TBL] [Abstract][Full Text] [Related]
27. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial.
Bafadhel M; McKenna S; Terry S; Mistry V; Pancholi M; Venge P; Lomas DA; Barer MR; Johnston SL; Pavord ID; Brightling CE
Am J Respir Crit Care Med; 2012 Jul; 186(1):48-55. PubMed ID: 22447964
[TBL] [Abstract][Full Text] [Related]
28. Non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine for the prevention of exacerbations in chronic obstructive pulmonary disease: a multicentre, randomised, placebo-controlled, observer-blinded, proof-of-concept, phase 2b trial.
Andreas S; Testa M; Boyer L; Brusselle G; Janssens W; Kerwin E; Papi A; Pek B; Puente-Maestu L; Saralaya D; Watz H; Wilkinson TMA; Casula D; Di Maro G; Lattanzi M; Moraschini L; Schoonbroodt S; Tasciotti A; Arora AK; Maltais F;
Lancet Respir Med; 2022 May; 10(5):435-446. PubMed ID: 35026180
[TBL] [Abstract][Full Text] [Related]
29. Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD).
Ni H; Htet A; Moe S
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD011897. PubMed ID: 28631387
[TBL] [Abstract][Full Text] [Related]
30. Prophylactic antibiotics for adults with chronic obstructive pulmonary disease: a network meta-analysis.
Janjua S; Mathioudakis AG; Fortescue R; Walker RA; Sharif S; Threapleton CJ; Dias S
Cochrane Database Syst Rev; 2021 Jan; 1(1):CD013198. PubMed ID: 33448349
[TBL] [Abstract][Full Text] [Related]
31. Person-centred experiential therapy versus cognitive behavioural therapy delivered in the English Improving Access to Psychological Therapies service for the treatment of moderate or severe depression (PRaCTICED): a pragmatic, randomised, non-inferiority trial.
Barkham M; Saxon D; Hardy GE; Bradburn M; Galloway D; Wickramasekera N; Keetharuth AD; Bower P; King M; Elliott R; Gabriel L; Kellett S; Shaw S; Wilkinson T; Connell J; Harrison P; Ardern K; Bishop-Edwards L; Ashley K; Ohlsen S; Pilling S; Waller G; Brazier JE
Lancet Psychiatry; 2021 Jun; 8(6):487-499. PubMed ID: 34000240
[TBL] [Abstract][Full Text] [Related]
32. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials.
Bafadhel M; Peterson S; De Blas MA; Calverley PM; Rennard SI; Richter K; Fagerås M
Lancet Respir Med; 2018 Feb; 6(2):117-126. PubMed ID: 29331313
[TBL] [Abstract][Full Text] [Related]
33. Plasma exchange and glucocorticoids to delay death or end-stage renal disease in anti-neutrophil cytoplasm antibody-associated vasculitis: PEXIVAS non-inferiority factorial RCT.
Jayne D; Walsh M; Merkel PA; Peh CA; Szpirt W; Puéchal X; Fujimoto S; Hawley C; Khalidi N; Jones R; Flossmann O; Wald R; Girard L; Levin A; Gregorini G; Harper L; Clark W; Pagnoux C; Specks U; Smyth L; Ito-Ihara T; de Zoysa J; Brezina B; Mazzetti A; McAlear CA; Reidlinger D; Mehta S; Ives N; Brettell EA; Jarrett H; Wheatley K; Broadhurst E; Casian A; Pusey CD
Health Technol Assess; 2022 Sep; 26(38):1-60. PubMed ID: 36155131
[TBL] [Abstract][Full Text] [Related]
34. Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial.
Yousuf AJ; Mohammed S; Carr L; Yavari Ramsheh M; Micieli C; Mistry V; Haldar K; Wright A; Novotny P; Parker S; Glover S; Finch J; Quann N; Brookes CL; Hobson R; Ibrahim W; Russell RJ; John C; Grimbaldeston MA; Choy DF; Cheung D; Steiner M; Greening NJ; Brightling CE
Lancet Respir Med; 2022 May; 10(5):469-477. PubMed ID: 35339234
[TBL] [Abstract][Full Text] [Related]
35. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial.
Ferguson GT; Rabe KF; Martinez FJ; Fabbri LM; Wang C; Ichinose M; Bourne E; Ballal S; Darken P; DeAngelis K; Aurivillius M; Dorinsky P; Reisner C
Lancet Respir Med; 2018 Oct; 6(10):747-758. PubMed ID: 30232048
[TBL] [Abstract][Full Text] [Related]
36. The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study.
McDowell PJ; Diver S; Yang F; Borg C; Busby J; Brown V; Shrimanker R; Cox C; Brightling CE; Chaudhuri R; Pavord ID; Heaney LG;
Lancet Respir Med; 2021 Oct; 9(10):1174-1184. PubMed ID: 33971168
[TBL] [Abstract][Full Text] [Related]
37. Effect of Theophylline as Adjunct to Inhaled Corticosteroids on Exacerbations in Patients With COPD: A Randomized Clinical Trial.
Devereux G; Cotton S; Fielding S; McMeekin N; Barnes PJ; Briggs A; Burns G; Chaudhuri R; Chrystyn H; Davies L; De Soyza A; Gompertz S; Haughney J; Innes K; Kaniewska J; Lee A; Morice A; Norrie J; Sullivan A; Wilson A; Price D
JAMA; 2018 Oct; 320(15):1548-1559. PubMed ID: 30326124
[TBL] [Abstract][Full Text] [Related]
38. Oral prednisolone in preschool children with virus-associated wheeze: a prospective, randomised, double-blind, placebo-controlled trial.
Foster SJ; Cooper MN; Oosterhof S; Borland ML
Lancet Respir Med; 2018 Feb; 6(2):97-106. PubMed ID: 29373235
[TBL] [Abstract][Full Text] [Related]
39. Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial.
Dinh A; Ropers J; Duran C; Davido B; Deconinck L; Matt M; Senard O; Lagrange A; Makhloufi S; Mellon G; de Lastours V; Bouchand F; Mathieu E; Kahn JE; Rouveix E; Grenet J; Dumoulin J; Chinet T; Pépin M; Delcey V; Diamantis S; Benhamou D; Vitrat V; Dombret MC; Renaud B; Perronne C; Claessens YE; Labarère J; Bedos JP; Aegerter P; Crémieux AC;
Lancet; 2021 Mar; 397(10280):1195-1203. PubMed ID: 33773631
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
Chupp GL; Bradford ES; Albers FC; Bratton DJ; Wang-Jairaj J; Nelsen LM; Trevor JL; Magnan A; Ten Brinke A
Lancet Respir Med; 2017 May; 5(5):390-400. PubMed ID: 28395936
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
